<DOC>
	<DOC>NCT02154087</DOC>
	<brief_summary>Assess the influence of HP802-247 on biochemical and cellular markers of inflammation in chronic venous leg ulcers</brief_summary>
	<brief_title>A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Leg Ulcer</mesh_term>
	<mesh_term>Varicose Ulcer</mesh_term>
	<criteria>Provide informed consent Age ≥ 18 years and of either sex Willing to comply with protocol instructions, including allowing all study assessments Have a venous leg ulcer (VLU) between the knee and ankle (at or above the malleolus), with a surface area ≥ 4.0 cm x cm and ≤ 15.0 cm x cm Venous insufficiency confirmed by duplex Doppler ultrasound examination for valvular or venous incompetence Arterial supply adequacy confirmed Target ulcer involves a full thickness skin loss, but WITHOUT exposure of tendon, muscle, or bone Target ulcer duration ≥ 12 weeks but ≤ 104 weeks (24 months). Acceptable state of health and nutrition History of anaphylaxis, serum sickness, or erythema multiforme reaction to aprotinin, bovine serum albumin or bovine serum proteins, penicillin, streptomycin, amphotericin B or any other component of HP802247,or known sensitivity to Iodine Prior diagnosis of Systemic Lupus Erythematosus with elevated antiDNA antibody titers, Buerger's disease (thromboangiitis obliterans), current diagnosis of vasculitis, or current diagnosis of claudication Therapy with another investigational agent within thirty (30) days of Screening, or during the study, or any participation in a previous HP802247 trial A target ulcer of nonvenous etiologies (e.g., sickle cell anemia, necrobiosis lipoidica diabeticorum, pyoderma gangrenosum, vasculopathic or vasculitic) Documented history of osteomyelitis at the target wound location within 6 months preceding the Screening Visit Refusal of or inability to tolerate compression therapy Therapy of the target ulcer with Collagenase Santyl® ointment, autologous skin graft, biological dressings or living cell products (e.g., Oasis®, Apligraf™, Dermagraft™) within 30 days preceding the Screening Visit Therapy of the target ulcer with topical growth factors within 1 week preceding the Screening Visit Current therapy with systemic antibiotics Current systemic therapy with cytotoxic drugs Current therapy with chronic (&gt; 10 days) oral corticosteroids Current therapy with TNFα inhibitors History of cancer in the preceding 5 years (other than carcinoma in situ of the cervix or adequately treated nonmelanoma skin cancers)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Venous leg ulcer</keyword>
	<keyword>Ulcer</keyword>
	<keyword>Venous stasis</keyword>
	<keyword>Compression</keyword>
</DOC>